Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 674-683

  Shapiro, C L ^a   Ayash, L ^a   Webb, I J ^a   Gelman, R ^a   Keating, J ^a   Williams, L ^a   Demetri, G ^a   Clark, P ^a   Elias, A ^a   Duggan, D ^a   Hayes, D ^a   Hurd, D ^a   Henderson, I C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BURST FORMING UNIT E; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLONY FORMING UNIT GM; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LEUKOPENIA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031034850     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.674     Document Type: Article

References (44)

1. Peters WP: High-dose chemotherapy and autologous bone marrow support for breast cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology 1992. Philadelphia, PA. Lippincott, 1992, pp 135-150
2. Ayash L, Wheeler C, Fairclough D, et al.: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995
3. Eddy DM: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10:657-670, 1992
4. Antman K, Ayash L, Elias A, et al.: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
5. Livingston RB: Dose intensity and high dose therapy: Two different concepts. Cancer 74:1177-1183, 1994 (suppl)
6. Teicher BA, Holden SA, Eder JP, et al.: Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 49:5594-5998, 1989
7. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977
8. Skipper H: Dose intensity versus total dose of chemotherapy: An experimental basis, in DeVita VJ, Hellman S, Rosenberg S (eds): Important Advances in Oncology 1990. Philadelphia, PA, Lippincott, 1990, pp 43-64
9. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
10. Tepler I, Cannistra SA, Freii E III, et al.: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive out-patient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 11:1583-1591, 1993
11. Crown J, Kritz A, Vahdat L, et al.: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients wtih metastatic breast cancer. J Clin Oncol 11:1144-1149, 1993
12. Shea TC, Mason JR, Storniolo AM, et al.: Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 10:464-473, 1992
13. Pettengell R, Woll P, Thatcher N, et al.: Multicyclic, dose-intensive chemotherapy supported bysequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 13:148-156, 1995
14. Patrone F, Ballestrero A, Ferrando F, et al.: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 13:840-846, 1995
15. Ayash LJ, Elias A, Wheeler C, et al.: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994
16. Elias AD, Ayash L, Anderson KC, et al.: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocytemacrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036-3044, 1992
17. Antman K, Eder J, Elias A, et al.: High-dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125, 1987
18. Webb I, Eickhoff C, Elias A, et al.: Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony stimulating factor (G-CSF): Implications for timing and yield of hematopoietic progenitor cell collections. Transfusion 36:160-167, 1996
19. Anderson K, Ritz J, Takvorian T, et al.: Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 69:597-604, 1987
20. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
21. Norton L, Day R: Potential innovations in scheduling of cancer chemotherapy, in DeVita VS, Hellman S, Rosenberg S (eds): Important Advances in Oncology 1991. Philadelphia, PA, Lippincott, 1991, pp 57-72
22. Ludwig Breast Cancer Study Group T: Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988
23. Early Breast Cancer Trialists' Collaborative Group T: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
24. Muss H, Case D, Read S, et al.: Induction (IND) chemotherapy (CRx) followed by maintenance (MNT) or observation (OBS) in women with metastatic breast cancer (MBC): A randomized trial of the Piedmont Oncology Association (POA). Proc Am Soc Clin Oncol 9:22, 1990 (abstr)
25. Coates A, Gebski V, Bishop JF, et al.: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490-1495, 1987
26. Livingston R, Collins C, Williams M, et al.: Determinants of outcome after consolidation for stage IV breast cancer with cyclophosphamide, etoposide and displatin (CEP). Proc Am Soc Clin Oncol 13:58, 1994 (abstr)
27. Broun E, Sledge G, Ansari R, et al.: Two cycles of high dose chemotherapy with autologous bone marrow rescue (ABMR) as initial treatment for stage IV breast cancer. Proc Am Soc Clin Oncol 13:85, 1994 (abstr)
28. Ho A, Mason J, Mulroney C, et al.: Sequential high-dose chemotherapy with alternating regimens and stem cell support for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 13:96, 1994 (abstr)
29. Somlo G, Doroshow J, Forman S, et al.: Double cycle (C) high-dose melphalan (MEL) and cisplatin (CDDP) followed by peripheral stem cell (PSC) rescue. Proc Am Soc Clin Oncol 13:104, 1994 (abstr)
30. Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233-245, 1996
31. Shea T, Mason J, Breslin M, et al.: Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 12:1012-1020, 1994
32. Haas R, Mohle R, Fruhauf S, et al.: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794, 1994
33. Hornung RL, Longo DL: Hematopoietic stem cell depletion by resorative growth factor regimens during repeated high dose therapy. Blood 80:77-83, 1992
34. Hillyer C, Tiegerman K, Berkman E: Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: Evaluation of a new cell separator. Transfusion 31:327-332, 1991
35. Comenzo R, Malachowski M, Miller K, et al.: Large-volume leukaphresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion 35:42-45, 1995
36. Brugger W, Berenson R, Mertelsmann R, et al.: Reconstitution of meatopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283-287, 1995
37. + cells into the myeloid lineage. Blood 80:1405-1412, 1992
38. + progenitor cells by stem cell factor, interleukin-1B (IL-1B), IL-6, IL-3, interferon-γ and erythropoietin. Blood 81:2579-2584, 1993
39. Shpall EJ, Jones RB, Bearman SI, et al.: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28-36, 1994
40. + cells and rapid hematopietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922-1932, 1995
41. Siena S, Bregni M, Brando B, et al.: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
42. Bolwell BJ, Fishleder A, Andresen SW, et al.: G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment. Bone Marrow Transplant 12:609-614, 1993
43. Bezwoda W, Seymour L, Dansey R: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
44. Ayash L, Antman K, Wheeler C, et al.: High-dose multimodality therapy with stem cell support for stage IIIB breast cancer: The DFCI/BIH experience. Proc Am Soc Clin Oncol 14:936, 1995 (abstr)